Immuron Ltd is an Australian biopharmaceutical company that develops oral immunotherapy products derived from hyperimmune bovine colostrum. Its main commercial product, Travelan, is a dietary supplement taken by travellers to help reduce the risk of travellers' diarrhoea. The company also develops prescription products for infectious diseases of the gut, including a candidate for Clostridioides difficile infection, and works with research and medical partners. Immuron is based in Melbourne, Australia, and its products are sold in several overseas markets.
Immuron Ltd trades under the code IMC on the Australian Securities Exchange in Australia, with its price quoted in Australian dollars (AUD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Market X-Ray · price-based
Weak price profile
Ranks #962 of 1815 on the Australian Securities Exchange · confidence High
What this score is, and is not
It describes how this stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is. That fundamental X-Ray needs financial statements, which we do not have for Australia yet.
TrendStrong
71/100
Trading above its long-term averages and near its highs.
See the numbers →
Above 200-day average12.5%
From 52-week high-57.4%
MomentumFair
62/100
Typical recent returns for this exchange.
See the numbers →
3-month return5.3%
6-month return29.0%
12-month, skipping last month-46.4%
Stability (higher is calmer)Weak
18/100
Volatile, with deep drawdowns.
See the numbers →
Volatility, 1 year (lower is calmer)112.5%
Worst drawdown, 1 year (smaller is calmer)-72.3%
LiquidityWeak
41/100
Thinly traded: prices can jump and exits can be hard.
See the numbers →
Avg daily value traded0.02M AUD
Zero-volume days25.0%
IncomeNone
–/100
Pays no dividend.
See the numbers →
Years with dividends0
Price-based X-Ray. The fundamental X-Ray (financial health, valuation, growth, fair value) is available for US stocks today. It will follow for Australia when fundamentals data for this market is added. All Australia stocks.
52-wk range 0.026 – 0.098Daily closes, split-adjusted
Signals
50-day average0.042
200-day average0.036
Golden/death cross (60d)Golden, 37 days ago
New 52-week highNo
Bullish RSI divergenceNo
Average daily range (ATR)0.003
Technical summary
Daily
Bearish
3 bullish · 5 neutral · 8 bearish
Weekly
Neutral
5 bullish · 1 neutral · 6 bearish
Monthly
Strongly bearish
1 bullish · 1 neutral · 6 bearish
Moving averages (daily)
SMA 10
0.04
Bearish
EMA 10
0.04
Bullish
SMA 20
0.04
Bearish
EMA 20
0.04
Bearish
SMA 50
0.04
Bearish
EMA 50
0.04
Bearish
SMA 100
0.04
Bullish
EMA 100
0.04
Bearish
SMA 200
0.04
Bullish
EMA 200
0.04
Bearish
Oscillators (daily)
RSI (14)
47.97
Neutral
MACD (12, 26)
0.00
Bearish
Momentum (12)
0.00
Neutral
Stochastic %K (14)
54.55
Neutral
Williams %R (14)
-45.45
Neutral
CCI (20)
-57.35
Neutral
Pivot points (classic, last session)
S3
0.03
S2
0.03
S1
0.04
Pivot
0.04
R1
0.04
R2
0.04
R3
0.05
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Prices are end-of-day closes in AUD. Educational only, not financial advice.
